Do analysts recommend TENX or TRLV?

Tenax Therapeutics presently has a consensus price target of $38.00, indicating a potential upside of 144.45%. Given Tenax Therapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe Tenax Therapeutics is more favorable than Trulieve Cannabis. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tenax Therapeutics 1 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 2.86 Trulieve Cannabis 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Which has better valuation & earnings, TENX or TRLV?

Trulieve Cannabis has higher revenue and earnings than Tenax Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Tenax Therapeutics N/A N/A -$52.60M -$1.40 N/A Trulieve Cannabis $1.17B 1.47 N/A N/A N/A

Is TENX or TRLV more profitable?

Trulieve Cannabis' return on equity of 0.00% beat Tenax Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Tenax Therapeutics N/A -56.32% -53.12% Trulieve Cannabis N/A N/A N/A

Does the media favor TENX or TRLV?

In the previous week, Trulieve Cannabis had 1 more articles in the media than Tenax Therapeutics. MarketBeat recorded 7 mentions for Trulieve Cannabis and 6 mentions for Tenax Therapeutics. Trulieve Cannabis' average media sentiment score of 0.21 beat Tenax Therapeutics' score of -0.04 indicating that Trulieve Cannabis is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tenax Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Trulieve Cannabis 2 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to TENX or VIR?

In the previous week, Tenax Therapeutics had 3 more articles in the media than Vir Biotechnology. MarketBeat recorded 6 mentions for Tenax Therapeutics and 3 mentions for Vir Biotechnology. Vir Biotechnology's average media sentiment score of 1.81 beat Tenax Therapeutics' score of -0.04 indicating that Vir Biotechnology is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tenax Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Vir Biotechnology 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media favor HROW or TENX?

In the previous week, Tenax Therapeutics had 4 more articles in the media than Harrow. MarketBeat recorded 6 mentions for Tenax Therapeutics and 2 mentions for Harrow. Harrow's average media sentiment score of 0.94 beat Tenax Therapeutics' score of -0.04 indicating that Harrow is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Harrow 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Tenax Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor TENX or IMCR?

In the previous week, Tenax Therapeutics and Tenax Therapeutics both had 6 articles in the media. Immunocore's average media sentiment score of 0.18 beat Tenax Therapeutics' score of -0.04 indicating that Immunocore is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tenax Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Immunocore 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher earnings and valuation, TENX or AVBP?

Tenax Therapeutics is trading at a lower price-to-earnings ratio than ArriVent BioPharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Tenax Therapeutics N/A N/A -$52.60M -$1.40 N/A ArriVent BioPharma N/A N/A -$166.31M -$3.47 N/A

Is TENX or AVBP more profitable?

ArriVent BioPharma's return on equity of -48.98% beat Tenax Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Tenax Therapeutics N/A -56.32% -53.12% ArriVent BioPharma N/A -48.98% -45.44%

Does the media favor TENX or AVBP?

In the previous week, Tenax Therapeutics had 2 more articles in the media than ArriVent BioPharma. MarketBeat recorded 6 mentions for Tenax Therapeutics and 4 mentions for ArriVent BioPharma. ArriVent BioPharma's average media sentiment score of 0.62 beat Tenax Therapeutics' score of -0.04 indicating that ArriVent BioPharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tenax Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral ArriVent BioPharma 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Tenax Therapeutics (TENX) Competitors

$15.52 -0.46 (-2.87%)

As of 11:58 AM Eastern

Compare

TENX vs. TRLV, VIR, HROW, IMCR, and AVBP

Should you buy Tenax Therapeutics stock or one of its competitors? MarketBeat compares Tenax Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Tenax Therapeutics include Trulieve Cannabis (TRLV), Vir Biotechnology (VIR), Harrow (HROW), Immunocore (IMCR), and ArriVent BioPharma (AVBP). These companies are all part of the "pharmaceutical products" industry.

How does Tenax Therapeutics compare to Trulieve Cannabis?

Tenax Therapeutics (NASDAQ:TENX) and Trulieve Cannabis (NYSE:TRLV) are both small-cap pharmaceutical products companies, but which is the better stock? We will compare the two companies based on the strength of their media sentiment, valuation, earnings, analyst recommendations, institutional ownership, dividends, profitability and risk.

Trulieve Cannabis has higher revenue and earnings than Tenax Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tenax Therapeutics	N/A	N/A	-$52.60M	-$1.40	N/A
Trulieve Cannabis	$1.17B	1.47	N/A	N/A	N/A

Trulieve Cannabis' return on equity of 0.00% beat Tenax Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tenax Therapeutics	N/A	-56.32%	-53.12%
Trulieve Cannabis	N/A	N/A	N/A

1.7% of Tenax Therapeutics shares are owned by institutional investors. 10.8% of Tenax Therapeutics shares are owned by insiders. Comparatively, 3.8% of Trulieve Cannabis shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, Trulieve Cannabis had 1 more articles in the media than Tenax Therapeutics. MarketBeat recorded 7 mentions for Trulieve Cannabis and 6 mentions for Tenax Therapeutics. Trulieve Cannabis' average media sentiment score of 0.21 beat Tenax Therapeutics' score of -0.04 indicating that Trulieve Cannabis is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tenax Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Trulieve Cannabis	2 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Tenax Therapeutics presently has a consensus price target of $38.00, indicating a potential upside of 144.45%. Given Tenax Therapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe Tenax Therapeutics is more favorable than Trulieve Cannabis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tenax Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86
Trulieve Cannabis	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

Summary

Tenax Therapeutics beats Trulieve Cannabis on 6 of the 11 factors compared between the two stocks.

How does Tenax Therapeutics compare to Vir Biotechnology?

Tenax Therapeutics (NASDAQ:TENX) and Vir Biotechnology (NASDAQ:VIR) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, valuation, profitability, media sentiment, earnings, analyst recommendations and dividends.

1.7% of Tenax Therapeutics shares are owned by institutional investors. Comparatively, 65.3% of Vir Biotechnology shares are owned by institutional investors. 10.8% of Tenax Therapeutics shares are owned by insiders. Comparatively, 2.9% of Vir Biotechnology shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Tenax Therapeutics has a net margin of 0.00% compared to Vir Biotechnology's net margin of -638.88%. Vir Biotechnology's return on equity of -53.31% beat Tenax Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tenax Therapeutics	N/A	-56.32%	-53.12%
Vir Biotechnology	-638.88%	-53.31%	-41.76%

In the previous week, Tenax Therapeutics had 3 more articles in the media than Vir Biotechnology. MarketBeat recorded 6 mentions for Tenax Therapeutics and 3 mentions for Vir Biotechnology. Vir Biotechnology's average media sentiment score of 1.81 beat Tenax Therapeutics' score of -0.04 indicating that Vir Biotechnology is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tenax Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Vir Biotechnology	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Tenax Therapeutics has higher earnings, but lower revenue than Vir Biotechnology. Tenax Therapeutics is trading at a lower price-to-earnings ratio than Vir Biotechnology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tenax Therapeutics	N/A	N/A	-$52.60M	-$1.40	N/A
Vir Biotechnology	$68.56M	23.49	-$437.99M	-$3.13	N/A

Tenax Therapeutics currently has a consensus target price of $38.00, suggesting a potential upside of 144.45%. Vir Biotechnology has a consensus target price of $20.88, suggesting a potential upside of 118.59%. Given Tenax Therapeutics' higher probable upside, research analysts clearly believe Tenax Therapeutics is more favorable than Vir Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tenax Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86
Vir Biotechnology	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89

Tenax Therapeutics has a beta of 0.92, meaning that its stock price is 8% less volatile than the broader market. Comparatively, Vir Biotechnology has a beta of 1.62, meaning that its stock price is 62% more volatile than the broader market.

Summary

Vir Biotechnology beats Tenax Therapeutics on 9 of the 15 factors compared between the two stocks.

How does Tenax Therapeutics compare to Harrow?

Harrow (NASDAQ:HROW) and Tenax Therapeutics (NASDAQ:TENX) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, media sentiment, valuation, risk, earnings, profitability, institutional ownership and analyst recommendations.

Harrow presently has a consensus target price of $69.43, indicating a potential upside of 67.44%. Tenax Therapeutics has a consensus target price of $38.00, indicating a potential upside of 144.45%. Given Tenax Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Tenax Therapeutics is more favorable than Harrow.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Harrow	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64
Tenax Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86

Harrow has a beta of 0.26, suggesting that its stock price is 74% less volatile than the broader market. Comparatively, Tenax Therapeutics has a beta of 0.92, suggesting that its stock price is 8% less volatile than the broader market.

72.8% of Harrow shares are owned by institutional investors. Comparatively, 1.7% of Tenax Therapeutics shares are owned by institutional investors. 12.8% of Harrow shares are owned by company insiders. Comparatively, 10.8% of Tenax Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Harrow has higher revenue and earnings than Tenax Therapeutics. Harrow is trading at a lower price-to-earnings ratio than Tenax Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Harrow	$272.30M	5.68	-$5.14M	-$0.41	N/A
Tenax Therapeutics	N/A	N/A	-$52.60M	-$1.40	N/A

Tenax Therapeutics has a net margin of 0.00% compared to Harrow's net margin of -5.57%. Harrow's return on equity of 19.59% beat Tenax Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Harrow	-5.57%	19.59%	2.26%
Tenax Therapeutics	N/A	-56.32%	-53.12%

In the previous week, Tenax Therapeutics had 4 more articles in the media than Harrow. MarketBeat recorded 6 mentions for Tenax Therapeutics and 2 mentions for Harrow. Harrow's average media sentiment score of 0.94 beat Tenax Therapeutics' score of -0.04 indicating that Harrow is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Harrow	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Tenax Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Harrow beats Tenax Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Tenax Therapeutics compare to Immunocore?

Tenax Therapeutics (NASDAQ:TENX) and Immunocore (NASDAQ:IMCR) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, dividends, risk, profitability, institutional ownership, earnings, analyst recommendations and valuation.

Tenax Therapeutics has a beta of 0.92, suggesting that its share price is 8% less volatile than the broader market. Comparatively, Immunocore has a beta of 0.73, suggesting that its share price is 27% less volatile than the broader market.

Tenax Therapeutics currently has a consensus target price of $38.00, indicating a potential upside of 144.45%. Immunocore has a consensus target price of $56.71, indicating a potential upside of 69.52%. Given Tenax Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Tenax Therapeutics is more favorable than Immunocore.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tenax Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86
Immunocore	1 Sell rating(s)	4 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.40

Immunocore has higher revenue and earnings than Tenax Therapeutics. Immunocore is trading at a lower price-to-earnings ratio than Tenax Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tenax Therapeutics	N/A	N/A	-$52.60M	-$1.40	N/A
Immunocore	$400.02M	4.25	-$35.51M	-$0.55	N/A

1.7% of Tenax Therapeutics shares are owned by institutional investors. Comparatively, 84.5% of Immunocore shares are owned by institutional investors. 10.8% of Tenax Therapeutics shares are owned by insiders. Comparatively, 10.1% of Immunocore shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Tenax Therapeutics and Tenax Therapeutics both had 6 articles in the media. Immunocore's average media sentiment score of 0.18 beat Tenax Therapeutics' score of -0.04 indicating that Immunocore is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tenax Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Immunocore	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

Tenax Therapeutics has a net margin of 0.00% compared to Immunocore's net margin of -6.68%. Immunocore's return on equity of -7.07% beat Tenax Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tenax Therapeutics	N/A	-56.32%	-53.12%
Immunocore	-6.68%	-7.07%	-2.55%

Summary

Tenax Therapeutics and Immunocore tied by winning 7 of the 14 factors compared between the two stocks.

How does Tenax Therapeutics compare to ArriVent BioPharma?

Tenax Therapeutics (NASDAQ:TENX) and ArriVent BioPharma (NASDAQ:AVBP) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, valuation, media sentiment, earnings, analyst recommendations, institutional ownership, profitability and risk.

1.7% of Tenax Therapeutics shares are owned by institutional investors. Comparatively, 9.5% of ArriVent BioPharma shares are owned by institutional investors. 10.8% of Tenax Therapeutics shares are owned by company insiders. Comparatively, 8.6% of ArriVent BioPharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Tenax Therapeutics currently has a consensus target price of $38.00, suggesting a potential upside of 144.45%. ArriVent BioPharma has a consensus target price of $44.83, suggesting a potential upside of 37.65%. Given Tenax Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Tenax Therapeutics is more favorable than ArriVent BioPharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tenax Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86
ArriVent BioPharma	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78

Tenax Therapeutics is trading at a lower price-to-earnings ratio than ArriVent BioPharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tenax Therapeutics	N/A	N/A	-$52.60M	-$1.40	N/A
ArriVent BioPharma	N/A	N/A	-$166.31M	-$3.47	N/A

Tenax Therapeutics has a beta of 0.92, meaning that its share price is 8% less volatile than the broader market. Comparatively, ArriVent BioPharma has a beta of 1.29, meaning that its share price is 29% more volatile than the broader market.

In the previous week, Tenax Therapeutics had 2 more articles in the media than ArriVent BioPharma. MarketBeat recorded 6 mentions for Tenax Therapeutics and 4 mentions for ArriVent BioPharma. ArriVent BioPharma's average media sentiment score of 0.62 beat Tenax Therapeutics' score of -0.04 indicating that ArriVent BioPharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tenax Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
ArriVent BioPharma	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

ArriVent BioPharma's return on equity of -48.98% beat Tenax Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tenax Therapeutics	N/A	-56.32%	-53.12%
ArriVent BioPharma	N/A	-48.98%	-45.44%

Summary

ArriVent BioPharma beats Tenax Therapeutics on 7 of the 13 factors compared between the two stocks.

Get Tenax Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TENX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TENX vs. The Competition

Export

Metric	Tenax Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$412.65M	$3.64B	$6.74B	$12.51B
Dividend Yield	N/A	2.20%	2.68%	8.00%
P/E Ratio	-11.11	21.01	26.90	24.39
Price / Sales	N/A	314.09	587.69	117.46
Price / Cash	N/A	61.98	29.22	49.36
Price / Book	1.49	8.50	10.92	6.33
Net Income	-$52.60M	$23.83M	$3.58B	$330.66M
7 Day Performance	-10.56%	-3.45%	-2.25%	-0.84%
1 Month Performance	35.41%	6.33%	3.08%	-0.26%
1 Year Performance	163.47%	48.44%	26.23%	19.99%

Tenax Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TENX Tenax Therapeutics	3.0259 of 5 stars	$15.52 -2.9%	$38.00 +144.8%	+173.9%	$413.69M	N/A	N/A	9	News Coverage Short Interest Increase Gap Down
TRLV Trulieve Cannabis	1.2046 of 5 stars	$8.87 +0.5%	N/A	N/A	$1.70B	$1.17B	N/A	9,000	News Coverage Analyst Downgrade Short Interest Increase
VIR Vir Biotechnology	2.6635 of 5 stars	$10.25 +2.3%	$20.88 +103.7%	+72.0%	$1.69B	$68.56M	N/A	580	News Coverage Positive News
HROW Harrow	4.2903 of 5 stars	$46.15 +2.7%	$69.43 +50.4%	+19.7%	$1.67B	$272.30M	N/A	180
IMCR Immunocore	3.3557 of 5 stars	$33.40 +4.6%	$56.71 +69.8%	-7.2%	$1.62B	$400.02M	N/A	320	Analyst Downgrade High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TENX) was last updated on 7/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Tenax Therapeutics (TENX) Competitors

TENX vs. TRLV, VIR, HROW, IMCR, and AVBP

How does Tenax Therapeutics compare to Trulieve Cannabis?

Summary

How does Tenax Therapeutics compare to Vir Biotechnology?

Summary

How does Tenax Therapeutics compare to Harrow?

Summary

How does Tenax Therapeutics compare to Immunocore?

Summary

How does Tenax Therapeutics compare to ArriVent BioPharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TENX vs. The Competition

Tenax Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Tenax Therapeutics (TENX) Competitors

TENX vs. TRLV, VIR, HROW, IMCR, and AVBP

How does Tenax Therapeutics compare to Trulieve Cannabis?

Which has better valuation & earnings, TENX or TRLV?

Is TENX or TRLV more profitable?

Do insiders and institutionals believe in TENX or TRLV?

Does the media favor TENX or TRLV?

Do analysts recommend TENX or TRLV?

Summary

How does Tenax Therapeutics compare to Vir Biotechnology?

Do insiders and institutionals hold more shares of TENX or VIR?

Is TENX or VIR more profitable?

Does the media refer more to TENX or VIR?

Which has preferable earnings & valuation, TENX or VIR?

Do analysts rate TENX or VIR?

Which has more volatility and risk, TENX or VIR?

Summary

How does Tenax Therapeutics compare to Harrow?

Do analysts rate HROW or TENX?

Which has more volatility & risk, HROW or TENX?

Do institutionals and insiders believe in HROW or TENX?

Which has preferable valuation and earnings, HROW or TENX?

Is HROW or TENX more profitable?

Does the media favor HROW or TENX?

Summary

How does Tenax Therapeutics compare to Immunocore?

Which has more risk & volatility, TENX or IMCR?

Do analysts recommend TENX or IMCR?

Which has better valuation & earnings, TENX or IMCR?

Do insiders & institutionals believe in TENX or IMCR?

Does the media favor TENX or IMCR?

Is TENX or IMCR more profitable?

Summary

How does Tenax Therapeutics compare to ArriVent BioPharma?

Do insiders and institutionals have more ownership in TENX or AVBP?

Do analysts rate TENX or AVBP?

Which has higher earnings and valuation, TENX or AVBP?

Which has more risk & volatility, TENX or AVBP?

Does the media favor TENX or AVBP?

Is TENX or AVBP more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TENX vs. The Competition

Tenax Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools